The efficacy of CD40 ligand blockade in discordant pig-to-rat islet xenotransplantation is correlated with an immunosuppresive effect of immunoglobulin

Transplantation

Volumn 79, Issue 2, 2005, Pages 157-164

  Wennberg, Lars ^a   Goto, Masafumi ^a   Maeda, Akira ^a   Song, Zhensung ^a   Benjamin, Christopher ^c   Groth, Carl G ^a   Korsgren, Olle ^b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c BIOGEN   (United States)

Author keywords

CD40 ligand; Immunoglobulin; Islets; Porcine; Xenotransplantation

Indexed keywords

CD40 LIGAND MONOCLONAL ANTIBODY; CYCLOSPORIN A; IMMUNOGLOBULIN ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; KEYHOLE LIMPET HEMOCYANIN MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY; RAPAMYCIN; TACROLIMUS; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY BLOOD LEVEL; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; GRAFT REJECTION; GRAFT SURVIVAL; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY CAPSULE; MALE; MONOTHERAPY; NONHUMAN; PANCREAS ISLET CELL; PANCREAS ISLET TRANSPLANTATION; PRIORITY JOURNAL; RAT; SWINE; TREATMENT OUTCOME; XENOTRANSPLANTATION;

ANIMALS; ANTIBODIES, MONOCLONAL; CD40 LIGAND; CYCLOSPORINE; FETAL TISSUE TRANSPLANTATION; GRAFT REJECTION; GRAFT SURVIVAL; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE AGENTS; ISLETS OF LANGERHANS TRANSPLANTATION; MALE; RATS; RATS, INBRED LEW; SWINE; TACROLIMUS; TRANSPLANTATION, HETEROLOGOUS;

EID: 12744274676     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000147317.96481.DB     Document Type: Article

References (51)

1. Yamada A, Sayegh MH. The CD154-CD40 costimulatory pathway in transplantation. Transplantation 2002; 73(1 suppl): S36.
2. Harlan DM, Kirk AD. Anti-CD 154 therapy to prevent graft rejection. Graft 1998; 1(2): 63.
3. Pearson TC, Trambley J, Odom K, et al. Anti-CD40 therapy extends renal allograft survival in rhesus macaques. Transplantation 2002; 74(7): 933.
4. Xu H, Tadaki DK, Elster EA, et al. Humanized anti-CD 154 antibody therapy for the treatment of allograft rejection in nonhuman primates: Efficacy and toxicity of a protocol using sirolimus, tacrolimus and daclizumab in a nonhuman primate renal allotransplant model. Transplantation 2002; 74(7): 940.
5. Kenyon NS, Fernandez LA, Lehmann R, et al. Long-term survival and function of intrahepatic islet allografts in baboons treated with humanized anti-CD154. Diabetes 1999; 48(7): 1473.
6. Montgomery SP, Hale DA, Hirshberg B, et al. Preclinical evaluation of tolerance induction protocols and islet transplantation in non-human primates. Immunol Rev 2001; 183: 214.
7. Cho CS, Burkly LC, Fechner JH Jr, et al. Successful conversion from conventional immunosuppression to anti-CD 154 monoclonal antibody costimulatory molecule blockade in rhesus renal allograft recipients, Transplantation 2001; 72(4): 587.
8. Kirk AD, Burkly LC, Batty DS, et al. Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates. Nat Med 1999; 5(6): 686.
9. Kover KL, Geng Z, Hess DM, et al. Anti-CD154 (CD40L) prevents recurrence of diabetes in islet isografts in the DR-BB rat. Diabetes 2000; 49(10): 1666.
10. Sidiropoulos PI, Boumpas DT. Lessons learned from anti-CD40L treatment in systemic lupus erythematosus patients. Lupus 2004; 13(5): 391.
11. Larsen CP, Elwood ET, Alexander DZ, et al. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature 1996; 381(6581): 434.
12. Li Y, Li XC, Zheng XX, et al. Blocking both signal 1 and signal 2 of T-cell activation prevents apoptosis of alloreactive T cells and induction of peripheral allograft tolerance. Nat Med 1999; 5(11): 1298.
13. Li Y, Zheng XX, Li XC, et al. Combined costimulation blockade plus rapamycin but not cyclosporine produces permanent engraftment. Transplantation 1998; 66(10): 1387.
14. Wells AD, Li XC, Li Y, et al. Requirement for T-cell apoptosis in the induction of peripheral transplantation tolerance. Nat Med 1999; 5(11): 1303.
15. Smiley ST, Csizmadia V, Gao W, et al. Differential effects of cyclosporine A, methylprednisolone, mycophenolate, and rapamycin on CD154 induction and requirement for NFkappaB: Implications for tolerance induction. Transplantation 2000; 70(3): 415.
16. Olack BJ, Jaramillo A, Benshoff ND, et al. Rejection of porcine islet xenografts mediated by CD4+ T cells activated through the indirect antigen recognition pathway. Xenotransplantation 2002; 9(6): 393.
17. Benda B, Karlsson-Parra A, Ridderstad A, et al. Xenograft rejection of porcine islet-like cell clusters in immunoglobulin- or Fc-receptor gamma-deficient mice. Transplantation 1996; 62(9): 1207.
18. Simeonovic CJ, Ceredig R, Wilson JD. Effect of GK1.5 monoclonal antibody dosage on survival of pig proislet xenografts in CD4+ T cell-depleted mice. Transplantation 1990; 49(5): 849.
19. Gordon EJ, Woda BA, Shultz LD, et al. Rat xenograft survival in mice treated with donor-specific transfusion and anti-CD154 antibody is enhanced by elimination of host CD4+ cells. Transplantation 2001; 71(2): 319.
20. Pierson RN III, Winn HJ, Russell PS, Auchincloss H Jr. Xenogeneic skin graft rejection is especially dependent on CD4+ T cells. J Exp Med 1989; 170(3): 991.
21. Friedman T, Smith RN, Colvin RB, et al. A critical role for human CD4+ T-cells in rejection of porcine islet cell xenografts. Diabetes 1999; 48(12): 2340.
22. Benda B, Sandberg JO, Holstad M, et al. T cells in islet-like cell cluster xenograft rejection: a study in the pig-to-mouse model. Transplantation 1998; 66(4): 435.
23. Murray AG, Nelson RC, Rayat GR, et al. Neonatal porcine islet cells induce human CD4+, but not CD8+, lymphocyte proliferation and resist cell-mediated cytolytic injury in vitro. Diabetes 1999; 48(9): 1713.
24. Bayry J, Thirion M, Misra N, et al. Mechanisms of action of intravenous immunoglobulin in autoimmune and inflammatory diseases. Neurol Sci 2003; 24(suppl 4): S217.
25. Kazatchkine MD, Kaveri SV. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 2001; 345(10): 747.
26. Korsgren O, Sandler S, Landstrom AS, et al. Large-scale production of fetal porcine pancreatic isletlike cell clusters: An experimental tool for studies of islet cell differentiation and xenotransplantation. Transplantation 1988; 45(3): 509.
27. Wennberg L, Karlsson-Parra A, Sundberg B, et al. Efficacy of immunosuppressive drugs in islet xenotransplantation: Leflunomide in combination with cyclosporine and mycophenolate mofetil prevents islet xenograft rejection in the pig-to-rat model. Transplantation 1997; 63(9): 1234.
28. Satake M, Kumagai-Braesch M, Kaowagashi N, et al. Kinetics and characteristics of xenoantibody formation in diabetic patients transplanted with fetal porcine islet cell clusters. Xenotransplantation 1994; 1: 24.
29. Casadei DH, del C Rial M, Opelz G, et al. A randomized and prospective study comparing treatment with high-dose intravenous immunoglobulin with monoclonal antibodies for rescue of kidney grafts with steroid-resistant rejection. Transplantation 2001; 71(1): 53.
30. Luke PP, Scantlebury VP, Jordan ML, et al. Reversal of steroid- and anti-lymphocyte antibody-resistant rejection using intravenous immunoglobulin (IVIG) in renal transplant recipients. Transplantation 2001; 72(3): 419.
31. Jordan SC, Quartel AW, Czer LS, et al. Posttransplant therapy using high-dose human immunoglobulin (intravenous gammaglobulin) to control acute humoral rejection in renal and cardiac allograft recipients and potential mechanism of action. Transplantation 1998; 66(6): 800.
32. Jordan SC, Vo A, Bunnapradist S, et al. Intravenous immune globulin treatment inhibits crossmatch positivity and allows for successful transplantation of incompatible organs in living-donor and cadaver recipients. Transplantation 2003; 76(4): 631.
33. Montgomery RA, Zachary AA, Racusen LC, et al. Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients. Transplantation 2000; 70(6): 887.
34. Magee JC, Collins BH, Harland RC, et al. Immunoglobulin prevents complement-mediated hyperacute rejection in swine-to-primate xenotransplantation. J Clin Invest 1995; 96(5): 2404.
35. Schussler O, Genevaz D, Latremouille C, et al. Intravenous immunoglobulins for therapeutic use contain anti-idiotypes against xenophile antibodies and prolong discordant graft survival. Clin Immunol Immunopathol 1998; 86(2): 183.
36. Roos A, Rieben R, Faber-Krol MC, et al. IgM-enriched human introvenous immunoglobulin strongly inhibits complement-dependent porcine cell cytotoxicity mediated by human xenoreactive antibodies. Xenotransplantation 2003; 10(6): 596.
37. Rieben R, Roos A, Muizert Y, et al. Immunoglobulin M-enriched human intravenous immunoglobulin prevents complement activation in vitro and in vivo in a rat model of acute inflammation. Blood 1999; 93(3): 942.
38. Korsgren O. Acute cellular xenograft rejection. Xenotransplantation 1997; 4: 11.
39. Benda B, Lycke N, Holstad M, et al. Delayed type hypersensitivity- associated cytokines in islet xenotransplantation: Limited efficacy of interleukin-2- and tumor necrosis factor-alpha-blockade in interferon-gamma receptor-deficient mice. Xenotransplantation 2000; 7(3): 206.
40. Koulmanda M, Kovarik J, Mandel TE. Cyclophosphamide, but not CTLA4Ig, prolongs survival of fetal pig islet grafts in anti-T cell monoclonal antibody-treated NOD mice. Xenotransplantation 1998; 5(3): 215.
41. Lehnert AM, Mottram PL, Han W, et al. Blockade of the CD28 and CD40 pathways result in the acceptance of pig and rat islet xenografts but not rat cardiac grafts in mice. Transpl Immunol 2001; 9(1): 51.
42. Sutherland RM, McKenzie BS, Zhan Y, et al. Anti-CD45RB antibody deters xenograft rejection by modulating T cell priming and homing. Int Immunol 2002; 14(8): 953.
43. Grochowiecki T, Gotoh M, Dono K, et al. Induction of unresponsiveness to islet xenograft by MMC treatment of graft and blockage of LFA-1/ICAM-1 pathway. Transplantation 2000; 69(8): 1567.
44. Markees TG, Appel MC, Noelle RJ, et al. Tolerance to islet xenografts induced by dual manipulation of antigen presentation and co-stimulation. Transplant Proc 1996; 28(2): 814.
45. Weber CJ, Hagler MK, Chryssochoos JT, et al. CTLA4-Ig prolongs survival of microencapsulated neonatal porcine islet xenografts in diabetic NOD mice. Cell Transplant 1997; 6(5): 505.
46. Benda B, Ljunggren HG, Peach R, et al. Co-stimulatory molecules in islet xenotransplantation: CTLA4Ig treatment in CD40 ligand-deficient mice. Cell Transplant 2002; 11(7): 715.
47. Zhan Y, Brady JL, Sutherland RM, et al. Without CD4 help, CD8 rejection of pig xenografts requires CD28 costimulation but not perforin killing. J Immunol 2001; 167(11): 6279.
48. Lenschow DJ, Zeng Y, Thistlethwaite JR, et al. Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4Ig. Science 1992; 257(5071): 789.
49. Lehnert AM, Yi S, Burgess JS, et al. Pancreatic islet xenograft tolerance after short-term costimulation blockade is associated with increased CD4+ T cell apoptosis but not immune deviation. Transplantation 2000; 69(6): 1176.
50. Gordon EJ, Markees TG, Phillips NE, et al. Prolonged survival of rat islet and skin xenografts in mice treated with donor splenocytes and anti-CD154 monoclonal antibody. Diabetes 1998; 47(8): 1199.
51. Kover KL, Geng Z, Hess D, et al. CD40/154 blockade and rejection of islet allografts in the streptozotocin and autoimmune diabetic rat. Pediatr Diabetes 2001; 2(4): 178.